

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

ANNOUNCEMENT
FOR PRELIMINARY INJUNCTION

Reference is made to the announcement of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**” or “**WuXi AppTec**”) dated June 11, 2026 for the litigation against the United States Department of Defense (the “**DoD**”) in connection with the designation of the Company on the DoD’s 1260H list (the “**1260H Designation**”).

WuXi AppTec strongly objects to this erroneous 1260H Designation and has taken legal actions to protect the interests of the Company and our shareholders, employees, partners and customers. Following the filing of our lawsuit against the DoD on June 11, 2026, we filed a motion for preliminary injunction with the U.S. District Court for the District of Columbia (the “**Court**”) on June 29, 2026 to seek enjoining the DoD from enforcing, implementing or taking any other action pursuant to the 1260H Designation. The Court held a hearing of our motion on July 22, 2026.

On August 7, 2026 (U.S. time), the Court issued a ruling on our motion for preliminary injunction. We welcome the Court’s decision to grant the preliminary injunction we petitioned for. This ruling relieves the Company from the immediate adverse consequences of the 1260H Designation during the judicial process challenging such designation. We continue to believe that the facts will prevail after an objective and fair judicial review.

In the meantime, our operations remain fully functional, and we remain focused on our commitment to serving our customers and the patients relying on the lifesaving and life-improving medicines they make.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, August 9, 2026

As of the date of this announcement, the Board comprises Dr. Ge Li, Dr. Minzhang Chen, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Xuesong Leng as independent non-executive Directors.

* *For identification purposes only*